Penumbra Inc. (PEN)

Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.

Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.

Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - ...

The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estim...

Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.

PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. AVO, TXO, PEN & STRA are well-poised to gain.

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.